Investigational New Drugs

, Volume 28, Issue 6, pp 887–894

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

  • Filippo Bellati
  • Chiara Napoletano
  • Ilary Ruscito
  • Maria Pastore
  • Milena Pernice
  • Morena Antonilli
  • Marianna Nuti
  • Pierluigi Benedetti Panici
SHORT REPORT

DOI: 10.1007/s10637-009-9351-4

Cite this article as:
Bellati, F., Napoletano, C., Ruscito, I. et al. Invest New Drugs (2010) 28: 887. doi:10.1007/s10637-009-9351-4

Summary

Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life. Here we report the case of a patient who benefited from complete resolution of ascites after low dose intraperitoneal administration of bevacizumab. Immunological analyses showed an initial increase in proportion and function of CD8+ effector T cells and a reduction of circulating Treg cells. A review of the current literature regarding bevacizumab in ovarian cancer is reported. Bevacizumab has shown a high efficacy in the treatment of ovarian cancer. Intraperitoneal administration induces an immune activation and appears promising in the treatment of malignant ascites.

Keywords

Ascites Bevacizumab Intraperitoneal Lymphocyte Ovarian Cancer 

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Filippo Bellati
    • 1
    • 2
    • 3
  • Chiara Napoletano
    • 2
  • Ilary Ruscito
    • 2
  • Maria Pastore
    • 1
  • Milena Pernice
    • 1
  • Morena Antonilli
    • 1
  • Marianna Nuti
    • 2
  • Pierluigi Benedetti Panici
    • 1
  1. 1.Institute of Gynecology and ObstetricsSapienza UniversityRomeItaly
  2. 2.Department of Experimental MedicineSapienza UniversityRomeItaly
  3. 3.Department of Gynecology and ObstetricsUniversity of Rome SapienzaRomeItaly